Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO

• Anne Cleasby,

  Affiliation Astex Pharmaceuticals, Cambridge, United Kingdom

  ⨯
• Jeff Yon,

  Affiliation Astex Pharmaceuticals, Cambridge, United Kingdom

  ⨯
• Philip J. Day,

  Affiliation Astex Pharmaceuticals, Cambridge, United Kingdom

  ⨯
• Caroline Richardson,

  Affiliation Astex Pharmaceuticals, Cambridge, United Kingdom

  ⨯
• Ian J. Tickle,

  Affiliation Astex Pharmaceuticals, Cambridge, United Kingdom

  ⨯
• Pamela A. Williams,

  Affiliation Astex Pharmaceuticals, Cambridge, United Kingdom

  ⨯
• James F. Callahan,

  Affiliation GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• Robin Carr,

  Affiliation GlaxoSmithKline, Stevenage, United Kingdom

  ⨯
• Nestor Concha,

  Affiliation GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Jeffrey K. Kerns,

  Affiliation GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• Hongwei Qi,

  Affiliation GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Thomas Sweitzer,

  Affiliation GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America

  ⨯
• Paris Ward,

  Affiliation GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• Thomas G. Davies

  * E-mail: tom.davies@astx.com

  Affiliation Astex Pharmaceuticals, Cambridge, United Kingdom

  ⨯